OLIVIA HUNTZINGER: Open Payments
NPI 1508322868 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$918 in 39 payments from 13 companies in 2025. Trend: 2023 $312 · 2024 $485 · 2025 $918
Food & beverage: $918
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $179 |
| Alkermes, Inc. | 5 | $150 |
| E.R. Squibb & Sons, L.L.C. | 5 | $137 |
| Janssen Pharmaceuticals, Inc | 4 | $102 |
| Otsuka America Pharmaceutical, Inc. | 3 | $83 |
| Lundbeck LLC | 3 | $75 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $64 |
| Vanda Pharmaceuticals Inc. | 1 | $39 |
| Almatica Pharma LLC | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $20 |
Products named: VRAYLAR, REXULTI, ARISTADA, COBENFY, CAPLYTA, INVEGA SUSTENNA, SPRAVATO, FANAPT.
Industry payments across NV — which companies pay providers there.
